How can we Use these New Antiemetics, Fosaprepitant, Aprepitant, and Palonosetron?
نویسندگان
چکیده
منابع مشابه
Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics.
Chemotherapy-induced nausea and vomiting (CINV) are among the most feared side effects of cancer treatment. With increasingly more complex chemotherapy treatments, CINV plays an important role in determining patients' quality of life, as well as when to halt potentially lifesaving therapy. Although significant progress has been made in the treatment of CINV, patients undergoing chemotherapy con...
متن کاملTolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.
Fosaprepitant is an intravenous formulation of aprepitant, an oral NK1 antagonist used to prevent chemotherapy-induced nausea and vomiting. This randomized study was designed to evaluate fosaprepitant in polysorbate 80 vehicle for tolerability and bioequivalency to aprepitant. Tolerability was assessed by physical and laboratory examinations and adverse events. Plasma collected for 72 hours was...
متن کاملHow can we enhance the value of laboratory tests?
Today, the pressures on the healthcare systems for the controlling of the costs are extreme and all sectors try to demonstrate the value of their services by justifying the activities and expenditures so the value can be describe in terms like quality, efficiency, effectiveness, patient satisfaction, cost effectiveness .The value of the lab testing is generally directed to their costs and the c...
متن کاملFosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting
INTRODUCTION The selective neurokinin-1 receptor antagonist aprepitant is effective in the treatment of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with both moderately and highly emetogenic chemotherapy. Fosaprepitant has been developed as an intravenous prodrug of aprepitant. AIMS To update the evidence underlying the use of fosaprepitant to prevent CINV. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2012
ISSN: 0923-7534
DOI: 10.1016/s0923-7534(20)32151-7